Drug · DIN 02552469
TYENNE
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 14, 2025; first marketed April 14, 2025.
- Drug Identification Number (DIN)
- 02552469
- Company (DIN owner)
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Tocilizumab L04AC07
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TOCILIZUMAB | 200 MG | 10 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 11, 2024: NOC 34185New Drug Submission (NDS)
Other DINs named TYENNE
- DIN 02552450 · Marketed
- DIN 02552477 · Marketed
- DIN 02552485 · Marketed
- DIN 02552493 · Marketed